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Abstract 
Background: Previous studies reported that elevated serum uric acid level was associated with 
greater coronary lipid plaque. Xanthine oxidoreductase (XOR) is a rate-limiting enzyme in purine 
metabolism and is believed to play important roles in coronary atherosclerosis. However, the 
relation between XOR and coronary lipid plaque is unclear.  
Methods: Patients with stable coronary artery disease undergoing elective percutaneous coronary 
intervention under near-infrared spectroscopy intravascular ultrasound (NIRS-IVUS) guidance 
were prospectively included. They were divided into 3 groups according to plasma XOR activities 
based on a previous report: low, normal, and high. Quantitative coronary angiography and gray-
scale IVUS were analyzed. The primary endpoint was coronary lipid plaques in a non-target vessel 
assessed by NIRS-IVUS with lipid core burden index (LCBI) and maximum LCBI in 4 mm 
(maxLCBI4mm).  
Results: Out of 68 patients, 26, 31, and 11 patients were classified as low, normal, and high XOR 
activity groups. Quantitative coronary angiography demonstrated that the high XOR activity group 
had longer lesion length, smaller minimum lumen diameter, and higher percentage of diameter 
stenosis in a non-target vessel among the 3 groups. Gray-scale IVUS analysis also showed smaller 
lumen area in the high XOR activity group than the others. LCBI (102.1±56.5 vs. 65.6±48.5 vs. 
55.6±37.8, p=0.04) and maxLCBI4mm (474.4±171.6 vs. 347.4±181.6, 294.0±155.9, p=0.04) in a 
non-target vessel were significantly higher in the high XOR group than in the normal and low 
groups. 
Conclusions: Elevated XOR activity was associated with coronary lipid-rich plaque in a non-target 
vessel in patients with stable coronary artery disease. 
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Introduction 
Hyperuricemia is associated with gout and the development of cardiovascular diseases such as 
hypertension, heart failure, stroke and coronary artery disease (CAD).1 In addition, elevated serum 
uric acid (SUA) level is a prognostic indicator in patients with acute myocardial infarction.2,3 
Previous studies showed that elevated SUA level was significantly correlated with greater lipid 
content of coronary artery plaque in non-culprit lesions assessed by integrated backscatter-
intravascular ultrasound (IB-IVUS),4,5 suggesting that SUA level is a possible surrogate marker of 
having vulnerable plaque which leads to subsequent coronary events in patients with CAD. 
However, whether elevated SUA level is an independent causal factor of coronary atherosclerosis 
and vulnerable plaque has been controversial, and the mechanism remains unclear.1 
 Xanthine oxidoreductase (XOR) is a rate-limiting enzyme in the last two steps of purine 
metabolism converting hypoxanthine to xanthine and xanthine to uric. Reactive oxygen species 
(ROS) are generated by activity of XOR during the process, which can promote endothelial 
dysfunction, leading to coronary atherosclerosis.6,7 XOR is believed to play a key role in having 
vulnerable plaque in patients with CAD.4 However, few studies have been directly evaluated the 
relation between plasma XOR activity and coronary lipid plaque because of low XOR activity in 
humans.8 Recently, a novel XOR assay provides sensitive and accurate measurement of human 
XOR activity,9,10 and intracoronary near-infrared spectroscopy (NIRS) can detect lipid-rich plaque 
with high accuracy.11 The aim of the present study was to investigate relation between plasma XOR 
activity and coronary lipid core plaque assessed by NIRS-IVUS in patients with stable CAD. 
 
Methods 
From June 2017 to December 2018, patients with stable CAD who underwent elective 
percutaneous coronary intervention (PCI) under NIRS-IVUS guidance at Chiba University 
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Hospital were prospectively enrolled. The major criteria for exclusion were patients with acute 
coronary syndrome (ACS), hemodialysis, and the use of XOR inhibitor. A total of 80 patients were 
enrolled, but following subjects were excluded because 1) NIRS-IVUS system was not used under 
operator’s discretion (n=5), 2) NIRS-IVUS catheter failed to cross neither culprit nor non-culprit 
arteries (n=6), and 3) XOR inhibitor was used (n=1). Thus, 68 patients were included in the present 
study. The ethical committee of Chiba University approved this study, and written informed 
consent was obtained from all participants. The present study was registered at the University 
Hospital Medical Information Network (UMIN) Clinical Trials Registry (UMIN000027855). 
 Blood samples were collected from all patients during PCI before intravenous heparin 
injection in the fasting state. Plasma XOR activity was assessed with a highly sensitive assay using 
stable isotope-labeled xanthine and combination of liquid chromatography and triple quadruple 
mass spectrometry (Sanwa Kagaku Kenkyusho CO., Ltd, Japan).9 Patients were divided into 3 
groups according to plasma XOR activities based on a previous report: low <33 pmol/100 μL/h; 
normal 33-120 pmol/100 μL/h; and high >120 pmol/100 μL/h.12 Serum uric acid, low- and high-
density lipoprotein cholesterol, triglyceride, fasting blood sugar, and glycated hemoglobin were 
also measured. Estimated glomerular filtration rate was calculated with the modification of diet in 
renal disease equation using the Japanese coefficient according to the Kidney Disease Outcomes 
Quality Initiative clinical guidelines.13  
 Coronary angiography was quantitatively analyzed by QAngio XA (Version 7.1, Medis 
Medical Imaging System BV, Leiden, the Netherlands). Reference vessel diameter, minimum 
lumen diameter, percentage diameter stenosis, and lesion length were measured by a program 
automatically. 
 All PCI procedures were performed under NIRS-IVUS guidance after intracoronary 
administration of nitrates. NIRS-IVUS catheter system comprised 3.2 Fr rapid-exchange catheter, 
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console with pullback and rotation device (TVC imaging systems, Infraredx, Burlington, USA). 
NIRS-IVUS catheter was advanced into the target vessel before pre-dilatation if possible and the 
non-target vessels, and was pulled back at a speed of 0.5 mm/s and 240 rpm from distal segment 
to ostium of coronary artery or guiding catheter. If NIRS-IVUS catheter could not cross the target 
lesion, pre-dilatation was allowed and NIRS-IVUS analysis was done before stent implantation. 
When NIRS-IVUS could not cross the non-target vessels, the coronary arteries were not assessed. 
In all cases, the operator was encouraged to image as much as possible in both target and non-target 
vessels. NIRS data before stent implantation were analyzed with TVC imaging systems to provide 
a quantitative estimate of the amount of lipid core plaque. The total lesion lipid core burden index 
(LCBI) and maximal LCBI over any 4 mm segment (maxLCBI4mm) were automatically calculated 
by the fraction of yellow pixels obtained from the chemogram, an image map derived from the 
NIRS measurements.14 These indices range from 0 to 1000, representing the percentage of lipid 
core in the investigated segment. If two non-target vessels were studied by NIRS-IVUS, the one 
with higher maxLCBI4mm was assessed as the non-target vessel. Grey-scale IVUS was also 
analyzed by computerized planimetry (EchoPlaque 3.0, Idec Systems, Mountain, View, USA) 
according to the consensus document.15,16 Lumen and external elastic membrane (EEM) cross-
sectional areas and plaque burden at the site of minimum lumen area within the total measured 
segment and within the maxLCBI4mm segment were measured.17 All NIRS-IVUS analysis was 
performed by experienced operators who were blinded to patients’ characteristics. The primary 
endpoint of the present study was the relation between XOR activities and LCBI or maxLCBI4mm 
in a non-target vessel as pre-dilation in the culprit vessel significantly alters these indices.18  
 Statistical analysis was performed with JMP Pro 13 software (SAS Institute, Cary, USA). 
All data are expressed as mean ± standard deviation or frequency (%). Continuous variables were 
compared with analysis of variance. Categorical data were compared with chi-square test or 
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Fisher’s exact test. To normalize the skewed distribution, log-transformed XOR activity was used 
as a continuous variable, while absolute values of plasma XOR activities divided study patients 
into 3 groups. The Pearson correlation coefficient was used for continuous variables. Univariable 
analysis was performed using linear regression analysis. The associated variables in univariable 
analyses (p <0.20) were included in the multivariable model to identify the independent predictors 
of LCBI and maxLCBI4mm. A value of P < 0.05 was considered statistically significant. 
 
Results 
Out of 68 patients, 26 (38%), 31 (46%), and 11 (16%) patients were classified as low, normal, and 
high XOR activity groups. Baseline patient characteristics were shown in table 1. Current smoker 
was frequently found in the high XOR activity group than the others. There was no significant 
correlation between SUA level and log-XOR activity (r=−0.002, p=0.98). Table 2 and 3 list 
angiographic and gray-scale IVUS findings. Quantitative coronary angiography demonstrated that 
the high XOR activity group had longer lesion length, smaller minimum lumen diameter, and 
higher percentage of diameter stenosis in a non-target vessel among the 3 groups (Table 2). In the 
present study, target and non-target vessels were studied with NIRS-IVUS in 26, 31, and 10 patients, 
and 22, 30, and 9 patients in low, normal, and high XOR activity groups. Pre-dilation was 
performed in 28 out of 67 target vessels (42%). Gray-scale IVUS analysis showed significantly 
smaller lumen area and numerically greater plaque burden within total measured segment in a non-
target vessel in the high XOR activity group than the others (Table 3).  
 Pull-back length of NIRS-IVUS in a target vessel (74.3±20.2 vs. 74.7±22.8 vs. 81.7±24.3 
mm, p=0.63) and a non-target vessel (66.0±25.7 vs. 63.4±21.2 vs. 72.6±23.9 mm, p=0.59) did not 
significantly differ among the 3 groups. Compared with the low and normal XOR activity groups, 
the high XOR activity group had significantly higher LCBI (55.6±37.8 vs. 65.6±48.5 vs. 
 7 
102.1±56.5, p=0.04) and maxLCBI4mm (294.0±155.9 vs. 347.4±181.6 vs. 474.4±171.6, p=0.04) in 
a non-target vessel (Figure 1), whereas LCBI (95.4±70.5 vs. 97.1±68.2 vs. 71.4±65.8, p=0.57) and 
maxLCBI4mm (463.4±218.7 vs. 412.1±211.8 vs. 325.5±172.2, p=0.21) in a target vessel were not 
different. Multivariable analyses showed prior coronary artery bypass grafting and log-XOR 
activity as significant independent predictors of LCBI in a non-target vessel (Table 4), and log-
XOR activity as predictors of maxLCBI4mm with marginal significance (Table S1). 
 
Discussion 
The present study showed that high XOR activity was found in 16% in patients with stable CAD 
undergoing elective PCI. Patients in the high XOR activity group had significantly smaller 
minimum lumen diameter and area, longer lesion length, and higher LCBI and maxLCBI4mm in a 
non-target vessel. Multivariable analysis demonstrated that XOR activity was associated with 
higher LCBI and maxLCBI4mm. To the best of our knowledge, this is the first study investigating 
the impact of XOR activity on coronary lipid core plaque.  
 We previously reported that elevated SUA level was correlated with greater lipid content 
of coronary plaque assessed by IB-IVUS in non-culprit lesions in patients with ACS.5 A subsequent 
study confirmed this finding in patients with ACS and stable CAD, although the relation of SUA 
level to coronary lipid plaque in patients with stable CAD was not significant.5 No significant 
relation between elevated SUA level and greater lipid plaque was observed in the present study 
probably due to different study populations (i.e. ACS vs. stable CAD). In these reports,4-5 XOR 
was speculated as a key factor to promote atherosclerotic plaque formation. However, the direct 
relation between XOR activity and coronary lipid plaque has not been studied. It was difficult to 
accurately measure plasma XOR because the activity is much lower in humans than in animals.8 
In the present study, a recently developed assay was used to quantify human XOR activity.9-10 
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Utilizing this novel and sensitive method, Otaki et al. determined the reference interval of XOR 
activity as 33-120 pmol/100 μL/h based on the results for 95% of normal control subjects, 
indicating only 2.5% of normal control have high XOR activity.12 In contrast, high XOR activity 
was observed in 16% in the present study population, suggesting that patients with CAD are likely 
to have higher XOR activity. XOR pathways are one of the major ROS-generating systems in the 
vascular vessels. XOR plays physiologic roles in inflammatory signaling, the regulation of nitric 
oxide production, and vascular function in the purine metabolism, while uric acid itself may have 
a protective role in vascular alterations. The ROS generated by XOR induces adipogenesis, 
endothelial dysfunction, and myocytes activation, leading to atherosclerosis and cardiovascular 
diseases.19 Furthermore, XOR was shown to directly contribute to the transformation of 
macrophages into foam cells and the development of atherosclerotic plaque.20 A previous report 
and the present study indicate that SUA level is not significantly associated with XOR activity.12 
It is plausible that higher XOR activity increases the risk of having vulnerable plaque beyond SUA 
level.  
 The present study demonstrates that LCBI and maxLCBI4mm in a non-target vessel 
assessed by NIRS-IVUS were significantly higher in the high XOR activity group. Although there 
is no head-to-head comparison, it is conceivable that NIRS-IVUS is one of the most accurate in 
vivo technologies for detecting lipid-rich plaque. The sensitivity of IB-IVUS for characterizing 
lipid pool was reportedly 84% using histology as a gold standard,21 while that of NIRS-IVUS was 
reported to be 90% in early investigations.11 Both LCBI and maxLCBI4mm in a non-target vessel 
have been shown to have prognostic impact in recent studies. The ATHEROREMO-NIRS study 
indicated that patients with LCBI ≥43 (the median value in the study) in a non-target vessel had a 
higher rate of cumulative 1-year events, a composite of death, non-fatal ACS and unplanned 
coronary revascularization, compared with their counterpart (16.7% vs. 4.0%, p=0.01).22 Another 
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retrospective study showed that patients with LCBI ≥77 in non-target vessels had higher incidence 
of major adverse cardiovascular events (cardiac death, ACS, unplanned revascularization, and 
stroke) at 5 years than those with LCBI <77 (58.0% vs. 13.1%, p=0.004).23 Patients with the highest 
quartile of maxLCBI4mm (≥360) in a non-target vessel in the combined dataset of the 
ATHEROREMO-NIRS and IBIS-3-NIRS sub-studies were reported to have the highest risk of 
major adverse cardiac during the median follow-up of 4.1 years.24 A prospective, single-center 
observational registry also showed that the major adverse cardiovascular and cerebrovascular 
events were more frequently observed in patients with maxLCBI4mm ≥400 in non-culprit segment 
than the counterpart during the mean follow-up of 603 days.14 The LCBI and maxLCBI4mm in the 
high XOR activity group (i.e. 102.1±56.5 and 474.4±171.6) were numerically higher than the cut-
off values in the previous studies, indicating that coronary lipid core plaques in high XOR activity 
group in the present study are clinically significant. Recently, a large-scale prospective cohort 
confirmed the predictive impact of LCBI and maxLCBI4mm.25 
 There is no clinical study examining the efficacy of SUA or XOR lowering therapy to 
reduce coronary lipid plaque and subsequent coronary events following PCI. XOR inhibitors such 
as allopurinol have been shown to improve endothelial function and oxidative stress in patients 
with stable CAD.26 A previous placebo-controlled randomized trial found that allopurinol 
significantly reduced the progression of carotid intima-media thickness.27 Although a recent 
randomized control trial did not show the benefit of SUA lowering therapy in reducing coronary 
events,28 active intervention on patients with high XOR activity might improve clinical outcomes. 
Further studies are warranted to elucidate weather XOR inhibition stabilizes lipid-rich plaque and 
reduces coronary events in patients with high XOR activity. 
 There are some limitations in the present study. This was a single-center study, and the 
sample size was relatively small. NIRS-IVUS was used to assess coronary lipid plaque in the 
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present study, however, the impact of other modalities enabling precise analysis of coronary plaque 
morphology (e.g. optical coherence tomography) is unknown.29-30 Although oxidative stress is one 
of the key factors in the process of XOR-induced atherosclerosis, oxidative stress markers (e.g. 
isoprostanes, 8-hydroxy-2’-deoxyguanosine, and thiobarbituric acid reactive substances) were not 
assessed in the present study.  
 In conclusions, high XOR activity was observed in 16% in patients who underwent 
elective PCI. Patients with high XOR activity had significantly smaller coronary lumen and area, 
longer lesion length, and higher LCBI and maxLCBI4mm in a non-target vessel, showing that 
elevated XOR activity was associated with coronary lipid-rich plaque in patients with stable CAD. 
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Figure 1. Coronary Lipid Core Plaque Assessed by Near-Infrared Spectroscopy 
Intravascular Ultrasound in a Non-Target Vessel 
 
Patients were divided into 3 groups according to plasma XOR activities based on a previous report: 
low <33 pmol/100 μL/h; normal 33-120 pmol/100 μL/h; and high >120 pmol/100 μL/h.12 
LCBI = lesion lipid core burden index; maxLCBI4mm = maximal LCBI over any 4 mm segment. 
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Table 1. Baseline patient characteristics 
Variable XOR activity  
Low 
(n=26) 
Normal 
(n=31) 
High 
(n=11) 
P value 
Age (years) 72.2±12.5 71.0±9.9 65.8±7.9 0.25 
Male 20 (77%) 27 (87%) 11 (100%) 0.18 
Body mass index (kg/m2) 23.1±3.8 25.0±2.8 25.2±5.4 0.11 
Hypertension 18 (69%) 22 (71%) 6 (55%) 0.59 
Diabetes mellitus 9 (35%) 16 (52%) 6 (55%) 0.36 
Dyslipidemia 19 (73%) 19 (61%) 10 (91%) 0.17 
Current smoker 3 (12%) 3 (10%) 6 (55%) 0.002 
Prior myocardial infarction 7 (27%) 7 (23%) 5 (45%) 0.34 
Prior PCI 10 (38%) 11 (35%) 8 (72%) 0.09 
Medication     
 Dual antiplatelet therapy 26 (100%) 31 (100%) 11 (100%) 1.00 
 Oral anticoagulant 0 (0%) 5 (16%) 1 (9%) 0.10 
 ACE-I or ARB 12 (46%) 14 (45%) 7 (63%) 0.55 
 β-blocker 8 (31%) 15 (48%) 4 (36%) 0.39 
 Calcium channel blocker 12 (46%) 15 (48%) 4 (36%) 0.79 
 Diuretic 4 (15%) 4 (13%) 1 (9%) 0.87 
 Statin 24 (92%) 24 (77%) 10 (91%) 0.24 
Laboratory data     
 HbA1c (%) 6.3±1.3 6.3±0.8 6.6±1.1 0.59 
 Blood sugar (mg/dL) 128±83 120±33 143±46 0.52 
 HDL-C (mg/dL) 52±15 50±12 56±29 0.61 
 LDL-C (mg/dL) 95±28 88±26 97±21 0.49 
 Triglyceride (mg/dL) 139±70 142±69 134±43 0.94 
 eGFR (ml/min/1.73 m2) 69.6±17.1 70.5±19.3 78.6±14.5 0.35 
 Serum uric acid (mg/dL) 5.6±1.6 5.5±1.6 5.5±0.8 0.97 
Values are mean ± standard deviation, or n (%).  
ACE-I = angiotensin converting enzyme inhibitor; ARB = angiotensin receptor blocker; eGFR = 
estimated glomerular filtration rate; HbA1c = glycated hemoglobin; HDL-C = high-density 
lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; PCI = percutaneous coronary 
intervention; XOR = xanthine oxidoreductase.  
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Table 2. Angiographic findings 
 XOR activity  
Low 
(n=26) 
Normal 
(n=31) 
High 
(n=11) 
P value 
Target vessel studied 26 31 10  
 Left anterior descending 16 (62%) 19 (61%) 0 (0%) 0.03 
 Left circumflex 4 (15%) 4 (13%) 4 (40%)  
 Right coronary artery 6 (23%) 8 (26%) 6 (60%)  
Pre-dilation performed 9 (35%) 12 (39%) 7 (70%) 0.14 
Non-target vessel studied 22 30 9  
 Left anterior descending 2 (9%) 8 (27%) 3 (33%) 0.22 
 Left circumflex 9 (41%) 15 (50%) 3 (33%)  
 Right coronary artery 11 (50%) 7 (23%) 3 (33%)  
Quantitative coronary angiography     
 Target vessel     
  Reference diameter (mm) 2.44±0.60 2.71±0.82 2.15±0.53 0.08 
  Minimum lumen diameter (mm) 0.93±0.45 0.97±0.42 0.69±0.29 0.17 
  Diameter stenosis (%) 61.5±15.9 63.9±11.5 67.3±11.9 0.51 
  Lesion length (mm) 34.2±18.5 27.5±12.6 35.3±23.6 0.24 
 Non-target vessel     
  Reference diameter (mm) 2.81±0.76 2.79±0.65 2.60±0.57 0.75 
  Minimum lumen diameter (mm) 1.87±0.57 1.98±0.62 1.34±0.46 0.03 
  Diameter stenosis (%) 32.7±12.7 29.4±12.1 47.3±17.9 0.005 
  Lesion length (mm) 8.4±6.5 7.0±4.0 12.5±6.0 0.04 
Values are mean ± standard deviation, or n (%).  
XOR = xanthine oxidoreductase. 
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Table 3. Gray-scale IVUS analysis 
 XOR activity  
Low 
(n=26) 
Normal 
(n=31) 
High 
(n=11) 
P value 
Target vessel     
  Within maxLCBI4mm     
   EEM area (mm2) 14.0±7.1 14.4±5.7 12.0±1.8 0.54 
   Plaque area (mm2) 10.3±5.5 10.5±4.7 8.7±2.0 0.57 
   Lumen area (mm2) 3.9±3.2 3.9±2.1 3.3±1.8 0.79 
   Plaque burden (%) 71.6±14.5 72.4±10.7 72.8±13.5 0.96 
  Within total measured segment     
   EEM area (mm2) 10.5±4.3 12.5±5.2 9.5±2.5 0.11 
   Plaque area (mm2) 8.3±3.9 9.5±4.5 7.4±2.4 0.30 
   Lumen area (mm2) 2.4±0.9 3.0±1.5 2.1±0.4 0.05 
   Plaque burden (%) 75.5±9.2 75.3±8.1 77.3±6.4 0.80 
Non-Target vessel     
  Within maxLCBI4mm     
   EEM area (mm2) 14.1±7.4 15.5±5.5 12.1±3.6 0.31 
   Plaque area (mm2) 8.7±4.3 9.3±3.7 8.5±2.8 0.77 
   Lumen area (mm2) 5.4±3.9 6.2±3.3 3.6±1.5 0.13 
   Plaque burden (%) 62.0±13.3 60.7±13.5 70.2±7.3 0.15 
  Within total measured segment     
   EEM area (mm2) 11.9±5.2 13.0±5.2 10.5±3.0 0.37 
   Plaque area (mm2) 8.0±4.2 7.8±3.4 7.6±2.8 0.95 
   Lumen area (mm2) 3.8±1.7 5.2±3.2 2.9±0.6 0.03 
   Plaque burden (%) 65.9±13.2 60.8±13.5 71.6±6.3 0.07 
Values are mean ± standard deviation, or n (%).  
EEM = External elastic membrane; IVUS = intravascular ultrasound; maxLCBI4mm = maximum 
lipid core burden index in 4mm; XOR = xanthine oxidoreductase. 
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Table 4. Predictors of LCBI in non-target vessels 
Variable 
 
Univariable  Multivariable 
r P value  b P value 
Age (years) −0.005 0.97    
Male 0.17 0.199  0.06 0.61 
Body mass index (kg/m2) 0.03 0.83    
Hypertension −0.08 0.55    
Diabetes mellitus −0.05 0.68    
Dyslipidemia 0.02 0.91    
Current smoker 0.05 0.69    
Prior myocardial infarction 0.08 0.52    
Prior PCI −0.04 0.75    
Prior CABG 0.39 0.002  0.36 0.003 
Laboratory data      
 HbA1c (%) 0.02 0.88    
 Blood sugar (mg/dL) 0.02 0.85    
 HDL-C (mg/dL) 0.04 0.74    
 LDL-C (mg/dL) 0.06 0.62    
 Triglyceride (mg/dL) −0.12 0.37    
 C-reactive protein (mg/dL) −0.06 0.66    
 eGFR (ml/min/1.73 m2) 0.04 0.74    
 Serum uric acid (mg/dL) 0.06 0.67    
 Log-XOR activity 0.35 0.006  0.31 0.01 
CABG = coronary artery bypass grafting; eGFR = estimated glomerular filtration rate; HbA1c = 
glycated hemoglobin; HDL-C = high-density lipoprotein cholesterol; LCBI = lipid core burden 
index; LDL-C = low-density lipoprotein cholesterol; XOR = xanthine oxidoreductase. 
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Table S1. Predictors of maxLCBI4mm in non-target vessels 
Variable 
 
Univariable  Multivariable 
r P value  b P value 
Age (years) 0.01 0.97    
Male 0.10 0.43    
Body mass index (kg/m2) 0.11 0.38    
Hypertension 0.10 0.45    
Diabetes mellitus −0.05 0.70    
Dyslipidemia 0.01 0.95    
Current smoker 0.04 0.79    
Prior myocardial infarction 0.15 0.25    
Prior PCI 0.05 0.68    
Prior CABG 0.20 0.13  0.18 0.16 
Laboratory data      
 HbA1c (%) −0.09 0.51    
 Blood sugar (mg/dL) −0.11 0.40    
 HDL-C (mg/dL) −0.02 0.90    
 LDL-C (mg/dL) −0.01 0.97    
 Triglyceride (mg/dL) −0.07 0.61    
 C-reactive protein (mg/dL) −0.03 0.80    
 eGFR (ml/min/1.73 m2) −0.05 0.72    
 Serum uric acid (mg/dL) 0.10 0.45    
 Log-XOR activity 0.25 0.051  0.24 0.06 
CABG = coronary artery bypass grafting; eGFR = estimated glomerular filtration rate; 
HbA1c = glycated hemoglobin; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-
density lipoprotein cholesterol; maxLCBI4mm = maximal lipid core burden index over any 4 mm 
segment; XOR = xanthine oxidoreductase 
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